SLNO Bathi resik saben saham sajrone 12 wulan pungkasan soleno.life

Monopolistic pricing for the treatment of Prader-Willi syndrome drives the price action for Soleno Therapeutics (SLNO), and the 12-month net income per share chart confirms this trend, where the current level is 1.78. Patent protection creates a formidable barrier to entry for competitors, although high capital requirements and reliance on a single drug create certain risks to business viability.
Rincian analitis lan laporan data perusahaan Soleno Therapeutics Corp (SLNO)

For Soleno Therapeutics (SLNO), which utilizes external cloud capacities and contract manufacturing, EPS TTM determines the actual efficiency of profit generation per share over a rolling year, excluding the impact of issuance. By analyzing the change in per-share profit over the last 12 months, an investor assesses the business model's ability to convert patent assets into net income while bypassing the operational costs of outsourcing.